StockNews.AI
NEO
StockNews.AI
202 days

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

1. NeoGenomics will report Q4 and full-year 2024 results on February 18, 2025. 2. A conference call will discuss financial results and highlights. 3. NeoGenomics specializes in oncology testing services globally. 4. The company serves pharmaceutical clients in drug development. 5. They operate accredited laboratories across the U.S. and in the UK.

Earnings
-2.17%Current Return
VS
+0.26%S&P 500
$15.1801/29 08:33 AM EDTEvent Start
$14.8501/30 03:16 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings reports typically have an uncertain impact on stock prices. Past earnings calls have seen stable reactions from investors.

How important is it?

Earnings announcements are critical for assessing future performance but current data is not predictive.

Why Short Term?

Immediate effects expected around the earnings release date. Long-term trends depend on ongoing performance and market conditions.

Related Companies

NEOCGRXRMDMDCO
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highlights. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com or by clicking here. The webcast will be archived and available for replay shortly after the conclusion of the call. To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code is 167039. About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.

Related News